Lumos Appoints Thermo Fisher Scientific as US Distributor for FebriDx®
16 September 2024
Lumos Diagnostics has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to distribute FebriDx® in the United States (US).
FebriDx is a rapid point-of-care (POC) respiratory test which delivers results in 10 minutes from a fingerstick blood sample. In July 2023, the US Food and Drug Administration cleared FebriDx to be marketed in the US as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology.
Lumos Diagnostics CEO and MD, Doug Ward, said:
“We are very pleased to announce this partnership with Fisher Healthcare for FebriDx distribution,” said Lumos Diagnostics CEO and MD, Doug Ward. “We look forward to working together to accelerate the growth of FebriDx via their network of customers across the US.”
Click here to read today’s ASX release.
FebriDx is a rapid point-of-care (POC) respiratory test which delivers results in 10 minutes from a fingerstick blood sample. In July 2023, the US Food and Drug Administration cleared FebriDx to be marketed in the US as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology.
Lumos Diagnostics CEO and MD, Doug Ward, said:
“We are very pleased to announce this partnership with Fisher Healthcare for FebriDx distribution,” said Lumos Diagnostics CEO and MD, Doug Ward. “We look forward to working together to accelerate the growth of FebriDx via their network of customers across the US.”
Click here to read today’s ASX release.
